DSM completes sale of Resins & Functional Materials businesses
Sale to Covestro agreed in September 2020 for an equity value of €1.6 billion has finalized today.
01 Apr 2021
Integrated Annual Report 2020
DSM's social, environmental & financial performance in 2020
Annual General Meeting 2021
Invitation to shareholders
- IAR
- AGM
Share price
Purpose-led, Performance-driven
DSM is a global science-based company operating in the fields of Nutrition, Health and Sustainable Living. Our business is centered around developing innovative solutions and large innovation projects addressing Nutrition & Health, Climate & Energy and Resources & Circularity to drive above market growth.
At a glance
Key facts and figures about DSM, our broad, global nutrition business and focused, high-quality, specialty materials portfolio and our people, planet & profit performance.
Results center
Annual Results published on 16 February confirm DSM delivered a solid financial performance in 2020 and achieved key milestones in the first full year of its Strategy 2021.
Share center
In 2019 DSM celebrated the 30th anniversary of its privatisation and our ordinary shares being listed on the Euronext Stock Exchange in Amsterdam, the Netherlands.
Headlines (continuing operations) 2020
€8,106m
Net sales
€7,998 in 2019
€1,534m
Adjusted EBITDA
€1,551 in 2019
18.9%
Adjusted EBITDA margin
19.4% in 2019
Nutrition
Our Nutrition cluster comprises DSM Nutritional Products, DSM Food Specialties and DSM Hydrocolloids. This cluster provides solutions for animal precision nutrition and feed, food & beverages, pharmaceuticals, medical nutrition, early life nutrition, nutrition improvement, dietary supplements, personalized nutrition and personal care.
We are active at all stages of the associated value chains, producing pure active ingredients, incorporating them into sophisticated forms and providing tailored premixes, forward solutions and branded consumer products. Our unique portfolio of products and services is global and highly diversified, serving customers and other stakeholders locally across an extensive range of end-markets worldwide.
€6,365m
Net sales
€6,028 in 2019. >80% of group net sales
€1,338m
Adjusted EBITDA
€1,250 in 2019
21.0%
Adjusted EBITDA margin
20.7% in 2019 & an ambition of >20%
€3,025m
Animal nutrition
Sales: ↑ (2019: €2,892)
Organic Growth: ↑8%
Volume Growth: ↑4%
Price Growth: ↑4%
50
Animal nutrition premix facilities
& 15 human nutrition premix facilities
€2,143m
Human nutrition
Sales: ↑ (2019: €2,046)
Organic Growth: ↑5%
Volume Growth: ↑7%
Price Growth: ↓2%
>€1bn
of sales
came from immunity-optimizing ingredients in 2020
€648m
Food Specialties
Sales: ↑ (2019: €572)
Sales: ↑13%
Organic Growth: ↑4%
#1
supplier
of energy-saving enzyme solutions to the global brewing industry
€404m
Personal Care
Sales: ↓ (2019: €425)
Sales: ↓5%
Organic Growth: ↓4%
>70%
of our skin care portfolio
is > 90% natural in origin
Materials
Our Materials cluster comprises DSM Engineering Materials and DSM Protective Materials. The cluster comprises a high-quality portfolio of specialty materials for global end-markets including electrical components and electronics, automotive, food packaging, medical, personal protection, commercial marine, and apparel. Through our advanced and sustainable solutions, we are meeting demand for safer materials, greater efficiency and improved environmental performance.
€1,518m
Net sales
€1,744 in 2019
€272m
Adjusted EBITDA
€372 in 2019
17.9%
Adjusted EBITDA margin
21.3% in 2019
-12%
Organic sales development
-9% in 2019
€1,217m
Engineering Materials
Sales: ↓ (2019: €1,406)
Volume Growth: ↓6%
100%
Renewable electricity
used to manufacture materials for Apple’s products
100%
of Engineering Materials portfolio
to contain alternatives with >25% recycled and/or bio-based content by 2030
€301m
Protective Materials
Sales: ↓ (2019: €338)
Volume Growth: ↓9%
1
metric ton
of bio-based Dyneema® generates < 5 tons CO2eq than fossil-based Dyneema®
Latest financial & regulatory news
-
-
DSM acquires Flavor & Fragrance bio-based intermediates business from Amyris
DSM acquires business consisting of 7 bio-based intermediate products to add to existing Aroma Ingredients portfolio.
31 Mar 2021
-
DSM announces repurchase of shares to cover stock dividend
DSM will repurchase 800,000 ordinary shares to cover commitments for the final stock dividend 2020.
16 Mar 2021
Our Investor Relations team are based in Heerlen, the Netherlands. The team provides key facts and figures, as well as shareholder information, to current and potential shareholders of DSM and to analysts. To that effect Investor Relations plans, prepares and organizes the written and oral communications with (potential) shareholders and financial analysts, deals with the stock exchange authorities and maintains the necessary databases, websites and brochures.
Dave Huizing
Vice President
Investor Relations
+31 45 578 2864
Sandra Segers
PA to Dave Huizing
Investor Relations
+31 45 578 2864
Anna Morello
Manager
Investor Relations
+31 45 578 2282
Marc Silvertand
Manager
Investor Relations
+31 45 578 2348
Daniel Uribe
Analyst
Investor Relations
+31 45 578 2864
Petra Volk
Support Officer
Investor Relations
+31 45 578 2511
Read more
-
Key financials
DSM's latest net sales from continuing operations, adjusted net earnings per ordinary share, balance sheet, income statement and cash flow statement
-
Factbooks
An introduction for investors and analysts to DSM, our Nutrition, Materials and Innovation Center clusters and our businesses.
-
Corporate Governance
We believe in doing business the right way: from our management and supervisory boards, to our code of business conduct, to our position papers and statements on key industry issues.